For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. If you need to see your provider, please contact us to see if a Video Visit is right for you. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.
Cardiothoracic Surgery

The Department of Cardiothoracic Surgery is a recognized leader in heart, lung and esophagus surgery. Our experience with complex cardiothoracic issues and knowledge of the latest advances have helped to establish NewYork-Presbyterian|Weill Cornell Medicine as a major referral center for cardiovascular and thoracic patients from around the world.

Cardiac Surgery

The Division of Cardiac Surgery provides expert care to patients who need:

  • Coronary artery bypass surgery
  • Valve repair/replacement
  • Surgery for adult congenital heart disease
  • Minimally Invasive Heart Surgery
  • Ventricular Assist Devices (VADs)
Learn More
Cardiac Surgery team

Thoracic Surgery

The Division of Thoracic Surgery offers the most advanced surgical care for:

  • Lung and esophageal cancers
  • Emphysema
  • Hyperhidrosis
  • Hiatal hernia
  • Pericardial & Pleural Effusions
  • Thoracentesis
Learn More
Thoracic Surgery team

Why Choose Weill Cornell?

NewYork-Presbyterian & Weill Cornell Medicine - Cardiothoracic Surgery

New Advances

Type of Sponsorship Associated with Differences Between Trials for Invasive Cardiovascular Treatments

Mario Gaudino, ROMA Trial, CABG, Invasive Cardiovascular Treatments, cardiovascular diseaseIn randomized clinical trials, commercial sponsorship influences how studies are designed and the results reported in ways that often benefit the study’s sponsor, Weill Cornell Medicine and NewYork-Presbyterian investigators report in a new study. The findings underscore the need to improve study design, reporting and guidelines to avoid bias in these trials, the authors say.

The study, published June 1 in JAMA Internal Medicine, focuses on coronary, vascular and structural interventional cardiology, and vascular and cardiac surgeries because of the enormous burden cardiovascular disease places on public health. In the United States, it accounts for approximately 800,000 deaths per year and 6 percent of total dollars spent on healthcare. A rigorous approach to evaluating new interventions for heart disease is critical.

“In medicine in general, but in particular cardiovascular medicine, we see randomized clinical trials as the best form of evidence,” said lead author Dr. Mario Gaudino, a professor in cardiothoracic surgery and director of translational and clinical research in cardiothoracic surgery at Weill Cornell Medicine, and a cardiovascular surgeon at NewYork-Presbyterian/Weill Cornell Medical Center. “Our practice is very heavily influenced by the results of randomized clinical trials. If those trials are not properly performed and reported, there’s a risk that we use the wrong strategy and don’t treat patients in the best possible way.”

Click here to learn more about this article

Recent invasive CV trials fall short on certain design aspects

Contemporary randomized clinical trials assessing invasive CV interventions are often small with short follow-up and limited power to identify large treatment effects, according to a study published in JAMA Internal Medicine.

The study also found that commercially supported trials were linked to differences in results, design and reporting. In particular, commercially supported trials were more likely to report favorable outcomes than other trials, and to report findings inconsistent with the trial results.

In this cross-sectional study, Mario F.L. Gaudino, MD, FEBCTS, Stephen and Suzanne Weiss Professor of Cardiothoracic Surgery at Weill Cornell Medicine, and colleagues analyzed data from 216 randomized clinical trials focused on vascular, coronary and structural interventional cardiology and vascular and cardiac surgeries.

Click here to learn more about the article

Free Event: Smoking and COVID-19: Expert Panel and Q&A

On #WorldNoTobaccoDay, Dr. @BrendonStilesMD of @WCM_CTSurgery & @nyphospital will discuss how #COVID19 affects the lungs/heart if you smoke/vape.

Brendon Stiles, Lung health, Heart, Covid-19, smoking, vaping, Tobacco Use

Population Health Sciences Grand Roounds - 05/20/20

Mario Gaudino, ROMA Trial

Clinical Trials

The Cardiothoracic Surgery Department conducts a robust clinical trials program to evaluate the effectiveness of new treatments and medications that have the potential to improve the management of patients with heart, lung, and esophageal disease. The outcomes of heart, lung, and esophageal operations can be improved with technical innovations.

Current Clinical Trials

 

US News & World Report Best Hospitals

The Weill Cornell Medicine's Department of Cardiothoracic Surgery is proud to partner with NewYork-Presbyterian, ranked #4 in Adult Cardiology & Heart Surgery Hospital in the nation and #1 in NYC by U.S. News and World Report.